… In conclusion, in this pre-specified analysis of the DAPA-CKD trial, we demonstrated that
dapagliflozin consistently prolonged survival regardless of various patient characteristics. The …

… Our findings in the IgA nephropathy subgroup of DAPA-CKD are consistent with findings
from other smaller, mechanistic trials of SGLT2 inhibitors in patients without diabetes. In a small, …

… on survival—an effect amplified in the presence of CKD and increased albuminuria. In this
analysis from the DAPA-CKD trial, we demonstrated that dapagliflozin, compared with placebo…

… Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease
with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we …

… in patients with CKD is unknown. We performed a pre-specified analysis of the DAPA-CKD
trial to investigate the effect of dapagliflozin on systolic blood pressure in patients with CKD, …

… Change in albuminuria was a pre-specified exploratory outcome of DAPA-CKD.
Regression in UACR stage, defined as a transition from macroalbuminuria (≥300 mg/g) to …

… and CKD progression rates for patients receiving dapagliflozin or placebo over a 10-year
time horizon. We derived treatment-specific CKD stage transition matrices using DAPA-CKD …

… endpoint in both DAPA-CKD and DAPA-HF trials and is the focus of this analysis. New-onset …
the reduction in risk of incident type 2 diabetes based on pre-specified baseline subgroups …

… Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified
analysis from the DAPA-CKD randomized controlled trial. Eur Heart J. 2021;42:1216-27. …

… , and pre-specified statistical analysis plan have been published previously [9]. Briefly,
we performed time-to-event analyses … All analyses presented here followed the intention-to-treat …